Quarterly ResultMay 15, 2026, 04:44 PM
PLUS THERAPEUTICS Q1 Net Loss $(6.95)M; Regains Nasdaq Bid Compliance
AI Summary
PLUS THERAPEUTICS, INC. reported a significantly reduced net loss of $(6.95) million for the first quarter of 2026, compared to $(17.40) million in the prior year, largely due to lower other expenses. The company also announced it has regained compliance with the Nasdaq Minimum Bid Requirement following a 1-for-25 reverse stock split. Despite these improvements, operating expenses increased, and the company continues to face a 'going concern' warning due to its ongoing need for additional financing.
Key Highlights
- Reported a net loss of $(6.95) million for Q1 2026, a significant reduction from $(17.40) million in Q1 2025.
- Grant revenue for Q1 2026 was $1.03 million, slightly down from $1.06 million in Q1 2025.
- Research and development expenses increased to $2.87 million in Q1 2026 from $1.76 million in Q1 2025.
- General and administrative expenses rose to $5.28 million in Q1 2026 from $2.84 million in Q1 2025.
- Cash and cash equivalents stood at $3.02 million as of March 31, 2026.
- Total stockholders' equity increased to $11.96 million as of March 31, 2026, from $3.99 million at Dec 31, 2025.
- Regained compliance with Nasdaq's Minimum Bid Requirement on April 20, 2026.
- Implemented a 1-for-25 reverse stock split effective April 2, 2026.
Price Impact
More from PSTV